MODELING THE BUDGET IMPACT OF AVAILABILITY OF BIOSIMILARS OF INFLIXIMAB AND ADALIMUMAB FOR TREATMENT FOR RHEUMATOID ARTHRITIS USING PUBLISHED CLAIM-BASED ALGORITHM DATA IN THE UNITED STATES
May 1, 2016, 00:00 AM
10.1016/j.jval.2016.03.1122
https://www.valueinhealthjournal.com/article/S1098-3015(16)01190-6/fulltext
Section Title :
Muscular-Skeletal Disorders - Cost Studies
Section Order :
792
First Page :
A228
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(16)01190-6&doi=10.1016/j.jval.2016.03.1122